Stifel analyst Annabel Samimy raised the firm’s price target on Apellis to $75 from $65 and keeps a Buy rating on the shares after the FDA approved Syfovre for the treatment of geographic atrophy secondary to age-related macular degeneration with "a broad label" that includes flexibility to dose according to patient needs and no unexpected safety findings over 24 months. The firm said it sees the approval "locking in its first-to-market position and quieting lingering concerns after an unconventional regulatory process."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on APLS:
- Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
- Apellis price target raised to $105 from $90 at Baird
- Apellis price target raised to $87 from $75 at H.C. Wainwright
- Apellis price target raised to $91 from $86 at Citi
